Kineta Receives New Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    219 Terry Ave N Seattle, WA 98109
  • Company Description
    Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The two drug programs funded by the investment partnership are ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune diseases and rOAS, a novel pan-viral therapeutic aimed at an array of malicious viruses for which there are few effective therapies.
  • M&A Terms
  • Venture Investor
    RLB Holdings

Trending on Xconomy